Hingmire Sachin S, Sambhus Mahesh B, Kelkar Dhananjay S, Joshi Sujit, Parikh Purvish M, Bharath R
Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Pune, India.
Department of Oncology, Asian Institute of Oncology, Mumbai, Maharashtra, India.
South Asian J Cancer. 2017 Apr-Jun;6(2):47-50. doi: 10.4103/sajc.sajc_68_17.
The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. However, such regimens of shorter duration trastuzumab therapy like FinHer, offered in view of economic constraints, may not be able to achieve globally comparable cure rates in early breast cancer especially with high-risk women with more than 3 lymph node positive.
Outcome of 21 patients with HER2 positive breast cancer was treated with short course trastuzumab combination chemotherapy in the adjuvant setting was studied.
Out of 21 patients 15 are alive and disease free with a follow up of up to 73 months (median follow up 42 months).
对于人表皮生长因子受体2阳性乳腺癌患者，辅助性短疗程9周曲妥珠单抗联合治疗通常被视为一种具有成本效益且安全的选择，对印度次大陆以及其他发展中国家也具有重要意义。然而，鉴于经济限制而提供的如FinHer方案这样的较短疗程曲妥珠单抗治疗，可能无法在早期乳腺癌中实现全球可比的治愈率，尤其是对于有3个以上淋巴结阳性的高危女性。
研究了21例HER2阳性乳腺癌患者在辅助治疗中接受短疗程曲妥珠单抗联合化疗的结果。
21例患者中有15例存活且无疾病，随访时间长达73个月（中位随访时间42个月）。
